AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
60 Degrees Pharma's B-FREE Study for Chronic Babesiosis Begins Patient Enrollment.
ByAinvest
Friday, Nov 21, 2025 8:05 am ET1min read
60 Degrees Pharmaceuticals has announced the opening of the Cohen Center for Recovery from Complex Chronic Diseases at Mount Sinai Icahn School of Medicine as the central study site for the B-FREE Chronic Babesiosis Study. The study will evaluate tafenoquine treatment for chronic babesiosis, a vector-borne disease with an estimated unmet medical need of 4,400 to 190,000 cases annually. The study will run for approximately 12 months and enroll up to 100 patients.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet